MRC1 and non-small cell lung carcinoma: Notably, the role of MMR genes has been recently explored in non-small cell lung cancer (NSCLC), and alterations were associated with improved efficacy of nivolumab (a PD-1 checkpoint inhibitor) (Rizvi et al. 2015).